Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3NET 2Tumor-Agnostic 1Thoracic 1Head & Neck 1

Conditions

Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × fosbretabulin × NET × Clear all
NCT02279602 2018-04-17

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Mateon Therapeutics

Phase 2 Completed
7 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Mateon Therapeutics

Phase 2 Completed
18 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡